Search

Your search keyword '"Protein Tyrosine Kinase Inhibitor"' showing total 25 results
Start Over Descriptor "Protein Tyrosine Kinase Inhibitor" Search Limiters Full Text
25 results on '"Protein Tyrosine Kinase Inhibitor"'

1. Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study

Author

Zambrotta, G, Nicolini, F, Assouline, S, Busque, L, Pungolino, E, Abruzzese, E, Miggiano, M, Elena, C, Alvarez-Larran, A, Triguero, A, Iurlo, A, Bucelli, C, Cerrano, M, Capodanno, I, Lunghi, F, le Coutre, P, Galimberti, S, Caocci, G, Maffioli, M, Stagno, F, Saussele, S, Piazza, R, Druker, B, Fava, C, Guglielmana, V, Colombo, F, Antolini, L, Gambacorti-Passerini, C, Zambrotta G. P. M., Nicolini F. E., Assouline S., Busque L., Pungolino E., Abruzzese E., Miggiano M. C., Elena C., Alvarez-Larran A., Triguero A., Iurlo A., Bucelli C., Cerrano M., Capodanno I., Lunghi F., le Coutre P., Galimberti S., Caocci G., Maffioli M., Stagno F., Saussele S., Piazza R., Druker B. J., Fava C., Guglielmana V., Colombo F., Antolini L., Gambacorti-Passerini C., Zambrotta, G, Nicolini, F, Assouline, S, Busque, L, Pungolino, E, Abruzzese, E, Miggiano, M, Elena, C, Alvarez-Larran, A, Triguero, A, Iurlo, A, Bucelli, C, Cerrano, M, Capodanno, I, Lunghi, F, le Coutre, P, Galimberti, S, Caocci, G, Maffioli, M, Stagno, F, Saussele, S, Piazza, R, Druker, B, Fava, C, Guglielmana, V, Colombo, F, Antolini, L, Gambacorti-Passerini, C, Zambrotta G. P. M., Nicolini F. E., Assouline S., Busque L., Pungolino E., Abruzzese E., Miggiano M. C., Elena C., Alvarez-Larran A., Triguero A., Iurlo A., Bucelli C., Cerrano M., Capodanno I., Lunghi F., le Coutre P., Galimberti S., Caocci G., Maffioli M., Stagno F., Saussele S., Piazza R., Druker B. J., Fava C., Guglielmana V., Colombo F., Antolini L., and Gambacorti-Passerini C.

Abstract

Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports of several such cases has raised concern. To estimate the risk of AP/BP among TD-eligible patients, we conducted TFR-PRO, a cohort retro-prospective study: 870 CP-CML patients eligible for TD formed a discontinuation cohort (505 patients) and a reference one (365 patients). The primary objective was the time adjusted rate (TAR) of progression in relation to TD. Secondary endpoints included the TAR of molecular relapse, that is, loss of major molecular response (MMR). With a median follow up of 5.5 years and 5188.2 person-years available, no events occurred in the TD cohort. One event of progression was registered 55 months after the end of TD, when the patient was contributing to the reference cohort. The TAR of progression was 0.019/100 person-years (95% CI [0.003–0.138]) in the overall group; 0.0 (95% CI [0–0.163]) in the discontinuation cohort; and 0.030 (95% CI [0.004–0.215]) in the reference cohort. These differences are not statistically significant. Molecular relapses occurred in 172/505 (34.1%) patients after TD, and in 64/365 (17.5%) patients in the reference cohort, p <.0001. Similar rates were observed in TD patients in first, second or third line of treatment. CML progression in patients eligible for TD is rare and not related to TD. Fears about the risk of disease progression among patients attempting TD should be dissipated.

Published
2023

2. Hunig's base catalyzed synthesis of new 1-(2,3-dihydro-1H-inden-1-yl)-3-aryl urea/thiourea derivatives as potent antioxidants and 2HCK enzyme growth inhibitors

Author

Lachhi, Reddy, V., Avula, V. K. R., Zyryanov, G. V., Vallela, S., Anireddy, J. S., Pasupuleti, V. R., Chamarthi, N. R., Зырянов, Г. В., Lachhi, Reddy, V., Avula, V. K. R., Zyryanov, G. V., Vallela, S., Anireddy, J. S., Pasupuleti, V. R., Chamarthi, N. R., and Зырянов, Г. В.

Abstract

A series of 1-(2,3-dihydro-1H-indan-1-yl)-3-aryl urea/thiourea derivatives (4a-j) have been synthesized from the reaction of 2,3-dihydro-1H-inden-1-amine (2) with various aryl isocyanates/isothiocyanates (3a-j) by using N,N-DIPEA base (Hunig's base) catalyst in THF at reflux conditions. All of them are structurally confirmed by spectral (IR, 1H & 13C NMR and MASS) and elemental analysis and screened for their in-vitro antioxidant activity against DPPH and NO free radicals and found that compounds 4b, 4i, 4h & 4g are potential antioxidants. The obtained in vitro results were compared with the molecular docking, ADMET, QSAR and bioactivity study results performed for them and identified that the recorded in silico binding affinities were observed in good correlation with the in vitro antioxidant results. The Molecular docking analysis had unveiled the strong hydrogen bonding interactions of synthesized ligands with ARG 160 residue of protein tyrosine kinase (2HCK) enzyme and plays an effective role in its inhibition. Toxicology studies have assessed the potential risks of 4a-j and inferred that all of them were in the limits of potential drugs. The conformational analysis of 4a-j inferred that the urea/thiourea spacer linking 2,3-dihydro-1H-inden-1-amino and substituted aryl units has facilitated all these molecules to effectively bind with ARG 160 amino acid residue present on the α-helix of the protein tyrosine kinase (2HCK) enzyme specifically on chain A of hemopoetic cell kinase. Collectively this study has established a relationship between the antioxidant potentiality and ligands binding with ARG 160 amino acid residue of chain A of 2HCK enzyme to inhibit its growth as well as proliferation of reactive oxygen species in vivo. © 2019 Elsevier Inc.

Published
2020

4. Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer.

Author

Munneke B., Brody J.D., Hernandez-Aya L., Bonomi P., Goldman J.W., Berim L., Renouf D.J., Goodwin R.A., Ho P.Y., Hsieh J., McCaffery I., Kwei L., Willingham S.B., Miller R.A., Fong L., Hotson A., Powderly J.D., Sznol M., Heist R.S., Choueiri T.K., George S., Hughes B.G.M., Hellmann M.D., Shepard D.R., Rini B.I., Kummar S., Weise A.M., Riese M.J., Markman B., Emens L.A., Mahadevan D., Luke J.J., Laport G., Munneke B., Brody J.D., Hernandez-Aya L., Bonomi P., Goldman J.W., Berim L., Renouf D.J., Goodwin R.A., Ho P.Y., Hsieh J., McCaffery I., Kwei L., Willingham S.B., Miller R.A., Fong L., Hotson A., Powderly J.D., Sznol M., Heist R.S., Choueiri T.K., George S., Hughes B.G.M., Hellmann M.D., Shepard D.R., Rini B.I., Kummar S., Weise A.M., Riese M.J., Markman B., Emens L.A., Mahadevan D., Luke J.J., and Laport G.

Abstract

Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial with a small-molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling in vivo. In a cohort of 68 patients with renal cell cancer (RCC), we also observe clinical responses alone and in combination with an anti-PD-L1 antibody, including subjects who had progressed on PD-1/PD-L1 inhibitors. Durable clinical benefit is associated with increased recruitment of CD8 + T cells into the tumor. Treatment can also broaden the circulating T-cell repertoire. Clinical responses are associated with an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-1/PD-L1 that restricts antitumor immunity. SIGNIFICANCE: This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent and anti-PD-L1 combination therapy in patients with refractory RCC. Responding patients possess an adenosine-regulated gene-expression signature in pretreatment tumor biopsies.Copyright © 2019 American Association for Cancer Research.

Published
2020

5. Synthesis, characterization, electrochemical behavior and in vitro protein tyrosine kinase inhibitory activity of the cymene-halogenobenzohydroxamato [Ru(η6-cymene)(bha)Cl] complexes

Author

Shang, Xianmei, Silva, Telma F.S., Martins, Luísa M.D.R.S., Li, Qingshan, Guedes da Silva, M. Fátima C., Kuznetsov, Maxim L., and Pombeiro, Armando J.L.

Subjects
*COMPLEX compounds synthesis, *PROTEIN-tyrosine kinases, *ENZYME inhibitors, *ORGANORUTHENIUM compounds, *ELECTROCHEMICAL analysis, *CYMENE, *SUBSTITUTION reactions
Abstract

Abstract: The ruthenium(II)–cymene complexes [Ru(η6-cymene)(bha)Cl] with substituted halogenobenzohydroxamato (bha) ligands (substituents = 4-F, 4-Cl, 4-Br, 2,4-F2, 3,4-F2, 2,5-F2, 2,6-F2) have been synthesized and characterized by elemental analysis, IR, 1H NMR, 13C NMR, cyclic voltammetry and controlled-potential electrolysis, and density functional theory (DFT) studies. The compositions of their frontier molecular orbitals (MOs) were established by DFT calculations, and the oxidation and reduction potentials are shown to follow the orders of the estimated vertical ionization potential and electron affinity, respectively. The electrochemical E L Lever parameter is estimated for the first time for the various bha ligands, which can thus be ordered according to their electron-donor character. All complexes exhibit very strong protein tyrosine kinase (PTK) inhibitory activity, even much higher than that of genistein, the clinically used PTK inhibitory drug. The complex containing the 2,4-difluorobenzohydroxamato ligand is the most active one, and the dependences of the PTK activity of the complexes and of their redox potentials on the ring substituents are discussed. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

6. Hunig's base catalyzed synthesis of new 1-(2,3-dihydro-1H-inden-1-yl)-3-aryl urea/thiourea derivatives as potent antioxidants and 2HCK enzyme growth inhibitors

Author

Swetha Vallela, Visweswara Rao Pasupuleti, Grigoriy V. Zyryanov, Venkataramana Lachhi Reddy, Naga Raju Chamarthi, Jaya Shree Anireddy, and Vijay Kumar Reddy Avula

Subjects
PHYSICAL CHEMISTRY, Antioxidant, medicine.medical_treatment, IC50, 01 natural sciences, Biochemistry, Antioxidants, PROTEIN TYROSINE KINASE, CELL NUCLEUS RECEPTOR, CHEMISTRY, ANTIOXIDANT, DRUG ABSORPTION, ELEMENTAL ANALYSIS, Drug Discovery, HUMAN CELL, Urea, chemistry.chemical_classification, HUMAN, THIOUREA DERIVATIVE, DRUG DISTRIBUTION, QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP, LIGANDS, PROTEIN KINASE INHIBITORS, IN VITRO STUDY, PROTEIN-TYROSINE KINASES, Stereochemistry, Radical, UREA/THIO-UREA DERIVATIVE, CARBON NUCLEAR MAGNETIC RESONANCE, Residue (chemistry), QUANTITATIVE STRUCTURE ACTIVITY RELATION, MDCK CELL LINE, 2,3-DIHYDRO-1H-INDEN-1-AMINE, NONHUMAN, Humans, FREE RADICAL, CACO-2 CELL LINE, DRUG METABOLISM, Molecular Biology, 010405 organic chemistry, CATALYSIS, 0104 chemical sciences, 1,1 DIPHENYL 2 PICRYLHYDRAZYL, PROTON NUCLEAR MAGNETIC RESONANCE, chemistry, CACO-2 CELLS, THIOUREA, MOLECULAR DOCKING STUDIES, NEUROPROTECTIVE AGENT, BLOOD-BRAIN BARRIER, DRUG EXCRETION, ELECTROSPRAY MASS SPECTROMETRY, MOLECULAR DOCKING SIMULATION, Quantitative Structure-Activity Relationship, UNCLASSIFIED DRUG, Ligands, chemistry.chemical_compound, PROTEIN KINASE INHIBITOR, ANTIOXIDANTS, MOLECULAR DOCKING, 1 (2,3 DIHYDRO 1H INDEN 1 YL) 3 (4 FLUOROPHENYL)UREA, PRIORITY JOURNAL, 2HCK ENZYME GROWTH INHIBITION, CATALYST, Hydrogen bond, Thiourea, HUMANS, Protein-Tyrosine Kinases, Molecular Docking Simulation, NEUROPROTECTIVE AGENTS, Neuroprotective Agents, BLOOD BRAIN BARRIER, Blood-Brain Barrier, ASCORBIC ACID, NUCLEOPHILICITY, PHOSPHOTRANSFERASE INHIBITOR, ADMET PROPERTIES, PLASMA PROTEIN BINDING, Catalysis, medicine, ARTICLE, Protein Kinase Inhibitors, Aryl, DRUG SYNTHESIS, Organic Chemistry, PROTEIN TYROSINE KINASE INHIBITOR, UREA DERIVATIVE, ULTRAVIOLET RADIATION, CONTROLLED STUDY, 010404 medicinal & biomolecular chemistry, Enzyme, ANIMAL CELL, CELL PROLIFERATION, THIN LAYER CHROMATOGRAPHY, LIGAND, UREA, Caco-2 Cells, PROTEINASE INHIBITOR, ANTIOXIDANT ACTIVITY
Abstract

A series of 1-(2,3-dihydro-1H-indan-1-yl)-3-aryl urea/thiourea derivatives (4a-j) have been synthesized from the reaction of 2,3-dihydro-1H-inden-1-amine (2) with various aryl isocyanates/isothiocyanates (3a-j) by using N,N-DIPEA base (Hunig's base) catalyst in THF at reflux conditions. All of them are structurally confirmed by spectral (IR, 1H & 13C NMR and MASS) and elemental analysis and screened for their in-vitro antioxidant activity against DPPH and NO free radicals and found that compounds 4b, 4i, 4h & 4g are potential antioxidants. The obtained in vitro results were compared with the molecular docking, ADMET, QSAR and bioactivity study results performed for them and identified that the recorded in silico binding affinities were observed in good correlation with the in vitro antioxidant results. The Molecular docking analysis had unveiled the strong hydrogen bonding interactions of synthesized ligands with ARG 160 residue of protein tyrosine kinase (2HCK) enzyme and plays an effective role in its inhibition. Toxicology studies have assessed the potential risks of 4a-j and inferred that all of them were in the limits of potential drugs. The conformational analysis of 4a-j inferred that the urea/thiourea spacer linking 2,3-dihydro-1H-inden-1-amino and substituted aryl units has facilitated all these molecules to effectively bind with ARG 160 amino acid residue present on the α-helix of the protein tyrosine kinase (2HCK) enzyme specifically on chain A of hemopoetic cell kinase. Collectively this study has established a relationship between the antioxidant potentiality and ligands binding with ARG 160 amino acid residue of chain A of 2HCK enzyme to inhibit its growth as well as proliferation of reactive oxygen species in vivo. © 2019 Elsevier Inc. One of the authors Dr. Avula Vijay Kumar Reddy is thankful to Ural Federal University, Yekaterinburg, Russian Federation for providing Postdoctoral Fellowship.

Published
2019

7. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia

Author

Meinolf Suttorp, Natacha Maledon, Frédéric Millot, Joelle Guilhot, Adalet Meral Güneş, Krzysztof Kałwak, Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri/Çocuk Sağlığı Ve Hastalıkları Bölümü., Güneş, Adalet Meral, CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pediatric Hematology and Oncology (MHH), and Hannover Medical School [Hannover] (MHH)

Subjects
0301 basic medicine, Male, Cancer Research, Time Factors, Survival, Databases, Factual, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Childhood leukemia, Recommendations, Leukemia relapse, Treatment response, Cancer staging, Time factor, European LeukemiaNet, 0302 clinical medicine, Immunophenotyping, Cancer Survivors, hemic and lymphatic diseases, Pathology, Overall survival, Molecular Targeted Therapy, Registries, Age of Onset, Child, Children, Priority journal, Chronic myeloid leukemia, Stem cell transplantation, Hematopoietic Stem Cell Transplantation, Register, Multicenter study, 3. Good health, Chronic Myeloid Leukemia, Imatinib, Protein Tyrosine Kinase Inhibitor, Clinical trial, Haematopoiesis, Retrospective study, Treatment Outcome, Oncology, Molecularly targeted therapy, 030220 oncology & carcinogenesis, Child, Preschool, International registry, Interphase-fish, Cml patients, Protein kinase inhibitor, Cancer survivor, Disease Progression, Female, Cancer chemotherapy, Chronic myelogenous leukemia, medicine.drug, Human, Adult, Adverse event, medicine.medical_specialty, Adolescent, Lymphoid blast crisis, Major clinical study, Blastic Phase, Article, 03 medical and health sciences, Internal medicine, Advanced cancer, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, Factual database, Prospective study, Disease exacerbation, Mortality, neoplasms, Survival rate, Protein tyrosine kinase inhibitor, Protein Kinase Inhibitors, Chronic myeloid leukaemia, Neoplasm Staging, Tyrosine kinase inhibitors, Chemotherapy, business.industry, Prognostic-factors, Infant, Follow up, Transplantation, 030104 developmental biology, Onset age, Preschool child, Comparative study, business, Controlled study
Abstract

Background Chronic myeloid leukaemia (CML) is very rare in children. The aim of the study is to report the experience within the I-CML-Ped study in children and adolescents presenting at diagnosis with advanced phase disease and to describe their characteristics and outcomes. Methods Of 479 children and adolescents enrolled in the international registry for childhood chronic myeloid leukaemia (I-CML-Ped Study; www.clinicaltrials.gov NCT01281735 ), 36 children (7.5%) presented at initial diagnosis with CML in advanced phase according to the European LeukemiaNet criteria. Results Nineteen (4%) patients were diagnosed in accelerated phase (CML-AP), and among the 17 patients (3.5%) diagnosed in blastic phase (CML-BP), 70% presented with lymphoid immunophenotype. Initial treatment of CML-AP/CML-BP consisted of tyrosine kinase inhibitors (TKIs) with or without chemotherapy, leading to complete haematologic response in 33 of 36 (92%) patients. Seventeen patients proceeded to haematopoietic stem cell transplantation. At the last follow-up, 18 of 19 patients with de novo CML-AP are alive in at least major molecular response (MMR) (n = 16), in progression (n = 1) or in molecular relapse (n = 1) and 13 of 17 patients with de novo CML-BP are alive in at least MMR. Five-year overall survival rates are 94% (95% confidence interval [CI]: 66%–99%) and 74% (95% CI: 44%–89%) for patients diagnosed in CML-AP and CML-BP, respectively. Conclusion Children with advanced phase at diagnosis of CML seem to have a better survival rate than that reported for advanced phases evolving under TKI treatment.

Published
2018

8. Sources and biological activities of marine sulfated steroids

Author

Carvalhal F., Correia-da-Silva M., Sousa E., Pinto M., Kijjoa A., and CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental

Subjects
antivirus agent, guanosine diphosphate, antiproliferative activity, marine environment, protein tyrosine kinase inhibitor, microtubule assembly, biological activity, antineoplastic activity, Review, protein kinase C inhibitor, antiparasitic agent, pregnane X receptor, angiogenesis, antibacterial activity, antibiotic agent, antifungal agent, human, antineoplastic agent, structure activity relation, nonhuman, steroid, antifungal activity, apoptosis, protein tyrosine kinase, antiinflammatory activity, clinical trial, antithrombocytic agent, protein kinase C delta, antifouling agent, beta secretase 1, priority journal, antihypertensive activity, cardiovascular agent, antiviral activity, osteoblast, matrix metalloproteinase 14, hemolysis, antiinflammatory agent, farnesoid X receptor
Abstract

Marine environment is rich in structurally unique molecules and can be an inspiring source of novel drugs. Currently, six marine-derived drugs are in the market with FDA approval and several more are in the clinical pipeline. Structurally diverse and complex secondary metabolites have been isolated from the marine world and these include sulfated steroids. Biological activities of nearly 150 marine sulfated steroids reported from 1978 to 2017 are compiled and described, namely antimicrobial, antitumor, cardiovascular and antifouling activities. Structure–activity relationship for each activity is discussed. © 2018 Society for Endocrinology. This work was supported through national funds provided by FCT/MCTES – Foundation for Science and Technology from the Minister of Science, Technology and Higher Education (PIDDAC) and European Regional Development Fund (ERDF) through the COMPETE – Programa Operacional Factores de Competitividade (POFC) programme, under the projects PTDC/ MAR-BIO/4694/2014 (reference POCI-01-0145-FEDER-016790; Project 3599 PPCDT – Promover a Produção Científica e Desenvolvimento Tecnológico e a Constituição de Redes Temáticas) and PTDC/AAG-TEC/0739/2014 (reference POCI-01-0145-FEDER-016793; Project 9471 RIDTI – Reforçar a Investigação, o Desenvolvimento Tecnológico e a Inovação) in the framework of the programme PT2020. The author acknowledges the Strategic Funding UID/Multi/04423/2013 provided by FCT – Foundation for Science and Technology and European Regional Development Fund (ERDF), in the framework of the programme PT2020.

Published
2018

9. Ynamide Click chemistry in development of triazole VEGFR2 TK modulators

Author

Gilles Hanquet, Gabriela Addová, Juraj Dobiaš, Margaréta Vojtičková, Andrej Boháč, Rengul Cetin-Atalay, and Deniz Yildirim

Subjects
Oxazole/1,2,3-triazole isosteric replacement, Molecular model, protein tyrosine kinase inhibitor, Protein Data Bank (RCSB PDB), 4 [4 [5 (ethylsulfonyl) 2 methoxyphenylamino] 1h 1,2,3 triazol 1 yl] 2 (pyridin 2 yl)phenol, VEGFR2 tyrosine kinase inhibition, CuACC Click chemistry, chemistry.chemical_compound, Drug Discovery, vasculotropin receptor 2, phosphatidylinositol 3 kinase, Oxazole, carcinoma cell line, Molecular Structure, Chemistry, 1,2,3 triazole derivative, General Medicine, unclassified drug, enzyme activity, PI3K/Akt pathway, Alkynes, click chemistry, Click chemistry, Cytotoxic activity in Huh-7 and Mahlavu, cytotoxicity, chemical reaction, liver cell carcinoma, Stereochemistry, Triazole, Antineoplastic Agents, Article, Structure-Activity Relationship, Cell Line, Tumor, Humans, Structure–activity relationship, controlled study, human, Ynamide, Binding site, Protein Kinase Inhibitors, Cell Proliferation, Pharmacology, Dose-Response Relationship, Drug, binding site, human cell, oxazole, Organic Chemistry, molecular docking, Triazoles, Amides, Vascular Endothelial Growth Factor Receptor-2, drug structure, concentration response, Docking (molecular), protein kinase B, drug synthesis, Click Chemistry, molecular model, Drug Screening Assays, Antitumor, hepatocellular carcinoma cell lines
Abstract

Structure novelty, chemical stability and synthetic feasibility attracted us to design 1,2,3-triazole compounds as potential inhibitors of VEGFR2 tyrosine kinase. Novel triazoles T1-T7 were proposed by oxazole (AAZ from PDB: 1Y6A)/1,2,3-triazole isosteric replacement, molecular modelling and docking. In order to enable synthesis of T1-T7 we developed a methodology for preparation of ynamide 22. Compound 22 was used for all Click chemistry reactions leading to triazoles T1-T3 and T6-T7. Among the obtained products, T1, T3 and T7 specifically bind VEGFR2 TK and modulate its activity by concentration dependent manner. Moreover predicted binding poses of T1-T7 in VEGFR2 TK were similar to the one known for the oxazole inhibitor AAZ (PDB: 1Y6A). Unfortunately the VEGFR2 inhibition by triazoles e.g. T3 and T7 is lower than that determined for their oxazole bioisosters T3-ox and AAZ, resp. Different electronic properties of 1,2,3-triazole/oxazole heterocyclic rings were proposed to be the main reason for the diminished affinity of T1-T3, T6 and T7 to an oxazole AAZ inhibitor binding site in VEGFR2 TK (PDB: 1Y6A or 1Y6B). Moreover T1-T3 and T6 were screened on cytotoxic activity against two human hepatocellular carcinoma cell lines. Selective cytotoxic activity of T2 against aggressive Mahlavu cells has been discovered indicating possible affinity of T2 to Mahlavu constitutionally active PI3K/Akt pathway. © 2015 Elsevier Masson SAS.

Published
2015

10. Clinical outcomes in patients with renal cell carcinoma with venous tumour thrombus: 10-year single centre experience.

Author

Pan D., Wang L., Tanny S., Appu S., Pan D., Wang L., Tanny S., and Appu S.

Abstract

Introduction and Objectives: To evaluate long-term outcomes in patients undergoing radical nephrectomy and tumour thrombectomy at Monash Health over the last 10 years. Method(s): We performed a retrospective analysis of 27 patients undergoing surgery between 2005 and 2015. Follow-up data were available for 24 patients. Data on clinical presentation, laboratory and imaging investigations, tumour characteristics, staging, operative details, complications, and long-term follow-up were evaluated. Result(s): Twenty-seven patients were included in the study (19 males, 8 females). Patients aged between 37- 80 years with a mean age of 61 years. Eighteen patients (67%) had nodal or distant metastasis at the time of diagnosis. According to AJCC tumour thrombus classifications - level I in 13 patients (48%), level II in 5 patients (19%) and level III in 2 patients (7%). Post-operative complications of Clavien-Dindo grade III or above occurred in 4 patients (15%). Four patients (15%) received adjuvant chemotherapy and 10 patients (37%) received tyrosine-kinase inhibitor (TKI) therapy post-operatively. Mean follow-up period in this cohort was 62 months. At the time of follow-up 21 patients (78%) were still alive. Of the 6 deaths, 4 patients died of metastatic RCC, 1 patient died during re-operation and the cause of death was not recorded for the last patient. Conclusion(s): Radical nephrectomy and tumour thrombectomy offer reasonable long-term survival in patients with locally advanced RCC. The complication rates at our centre are comparable with that of the literature.

Published
2017

11. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents

Author

Chi Kong Li, André Baruchel, Michael Dworzak, Joelle Guilhot, Farah Roula, Krzysztof Kałwak, Petr Sedlacek, Eveline S. J. M. de Bont, Birgitte Lausen, Emilia Kaiserova, Barbara De Moerloose, Srdjana Culic, Frédéric Millot, Andrea Biondi, Adalet Meral Güneş, Meinolf Suttorp, Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Anabilim Dalı., Güneş, Adalet Meral, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL), Millot, F, Guilhot, J, Suttorp, M, Gunes, A, Sedlacek, P, De Bont, E, Li, C, Kalwak, K, Lausen, B, Culic, S, Dworzak, M, Kaiserova, E, De Moerloose, B, Roula, F, Biondi, A, and Baruchel, A

Subjects
Registrie, Male, Scoring system, Intermediate risk patient, 0302 clinical medicine, Low risk patient, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Overall survival, Registries, Disease free survival, Child, MOLECULAR RESPONSE, CHRONIC MYELOGENOUS LEUKEMIA, Myeloid leukemia, Hematology, Register, Prognosis, Acute graft versus host disease, Chronic Myeloid Leukemia, Imatinib, Protein Tyrosine Kinase Inhibitor, Leukemia, Treatment Outcome, Antineoplastic agent, 030220 oncology & carcinogenesis, Child, Preschool, Cohort, Disease Progression, Female, Infection, medicine.drug, Human, Adult, medicine.medical_specialty, 2904 CML PATIENTS, Adolescent, Prognosi, Long term survival score, Alpha interferon, Hemoglobin blood level, Major clinical study, IMATINIB, Disease-Free Survival, Article, Follow-Up Studie, Spleen size, 03 medical and health sciences, EUROPEAN LEUKEMIANET, Median follow-up, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, Disease exacerbation, Mortality, Survival rate, EUTOS score, Cancer prognosis, Antineoplastic Combined Chemotherapy Protocol, business.industry, Infant, Follow up, medicine.disease, Prognostic discrimination, YOUNGER PATIENTS, CHRONIC GRANULOCYTIC-LEUKEMIA, RANDOMIZED CML, Cancer survival, High risk patient, POPULATION-BASED REGISTRY, Leukocyte count, Preschool child, Immunology, Progression free survival, School child, INTERFERON-ALPHA, business, 030215 immunology, Chronic myelogenous leukemia, Follow-Up Studies
Abstract

The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P

Published
2017

12. Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells† †The authors declare no competing interests. ‡ ‡Electronic supplementary information (ESI) available. See DOI: 10.1039/c6md00392c

Author

Gilles Hanquet, Steve Lanners, Loïc Jeanmart, Peter Šramel, Deniz Cansen Kahraman, Rengul Cetin-Atalay, Andrej Boháč, Laboratoire d'innovation moléculaire et applications (LIMA), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de chimie moléculaire (LCM), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Substances naturelles/chimie moléculaire, Université Louis Pasteur - Strasbourg I-Ecole européenne de chimie, polymères et matériaux [Strasbourg]-Centre National de la Recherche Scientifique (CNRS), and Université de Strasbourg (UNISTRA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Unclassified drug, VEGF receptors, Pharmaceutical Science, Drug structure, Cancer cell, IC50, Bioinformatics, Biochemistry, Gene, 0302 clinical medicine, SYNCAT, Epithelial cell adhesion molecule, Quinoide, Drug Discovery, Cytotoxic T cell, Medicine, CD133 antigen, media_common, Protein p53, biology, [CHIM.ORGA]Chemical Sciences/Organic chemistry, Sorafenib, Liver cell carcinoma, 3. Good health, Chemistry, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Molecular Medicine, Drug mechanism, medicine.drug, Human, Drug, Drug cytotoxicity, Tumour heterogeneity, media_common.quotation_subject, Cell subpopulation, Beta catenin, Concentration response, Cell population, 03 medical and health sciences, Drug synthesis, Cancer stem cell, Drug approval, Vimentin, TP53 gene, Protein tyrosine kinase inhibitor, neoplasms, Antineoplastic activity, Pharmacology, business.industry, Organic Chemistry, Thy 1 antigen, Vasculotropin receptor 2, medicine.disease, digestive system diseases, Drug efficacy, 030104 developmental biology, Human cell, Cancer research, biology.protein, Protein expression, Transcription factor, business, Epithelial mesenchymal transition
Abstract

Bioactivities of quinoides 1-5 and VEGFR2 TKIs 6-10 in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC50 values in μM concentrations in HCC cells. Quinoide 3 was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor DAPT. However, the more cytotoxic VEFGR TKIs (IC50: 0.4-3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enriched the hepatocellular cancer stem cell population by 2-3 fold after treatment. An aggressiveness factor (AF) was proposed to quantify the characteristics of drug candidates for their ability to eradicate the CSC subpopulation. Considering the tumour heterogeneity and marker positive cancer stem cell like subpopulation enrichment upon treatments in patients, this study emphasises the importance of the chemotherapeutic agent choice acting differentially on all the subpopulations including marker-positive CSCs.

Published
2016
Full Text
View/download PDF

13. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review

Author

Boussios, Stergios, Seraj, E., Zarkavelis, George, Petrakis, Dimitrios, Kollas, Aristomenes, Kafantari, Aikaterini, Assi, A., Tatsi, K., Pavlidis, Nicholas, Pentheroudakis, George, Pavlidis, Nicholas [0000-0002-2195-9961], Pentheroudakis, George [0000-0002-6632-2462], Boussios, Stergios [0000-0002-2512-6131], and Zarkavelis, George [0000-0001-5961-2237]

Subjects
Oncology, Cancer therapy, Alkylating agent, medicine.medical_treatment, Cytotoxic t lymphocyte antigen 4 antibody, Cancer immunotherapy, Gimeracil plus oteracil potassium plus tegafur, Review, Gene, Cervix, Metastasis, 0302 clinical medicine, Squamous cell carcinoma, Pathology, Treatment outcome, Platinum compounds, Mammalian target of rapamycin inhibitor, Bevacizumab, Vincristine, Molecularly targeted therapy, 030220 oncology & carcinogenesis, Human, medicine.medical_specialty, Practice guideline, Uterine cervical neoplasms, Paclitaxel, Mitomycin, Adenocarcinoma, Altretamine, 03 medical and health sciences, Bleomycin, Cytotoxic t lymphocyte antigen 4, Vinorelbine tartrate, Humans, Ifosfamide, Neoplasms, Squamous Cell, Food and drug administration, Protein tyrosine kinase inhibitor, Cancer recurrence, Targeted agents, Cisplatin, Lymph node metastasis, Epidermal growth factor receptor, Somatic mutation, medicine.disease, 030104 developmental biology, 0301 basic medicine, Vinca alkaloid, Antimetabolite, Virus oncogene, Uterine Cervical Neoplasms, Platinum Compounds, Recurrence, Neoplasms, Cancer vaccine, Recurrent disease, Overall survival, Cervical cancer, Platinum derivative, Platinum complex, Mammalian target of rapamycin, Hematology, Programmed death 1 receptor, Dna topoisomerase inhibitor, Treatment Outcome, Cancer radiotherapy, Trend study, Female, Uterine cervix cancer, medicine.drug, Quality of life, Paraaortic lymph node, Pemetrexed, Vinorelbine, Pi3kca gene, Internal medicine, Advanced cancer, medicine, Drug approval, Chemotherapy, Pentoxifylline, Vasculotropin, business.industry, United states, Squamous cell, Cancer, Taxane derivative, Gemcitabine, Surgery, Drug efficacy, Quality of Life, Topotecan, Drug treatment failure, business, Unindexed drug
Abstract

Background Cervical cancer is the fourth most common cancer affecting women worldwide. Despite advances in screening and human papillomavirus (HPV) vaccination, a significant number of women present with or develop advanced disease. Palliative platinum-based chemotherapy (CT) is the standard first-line treatment for metastatic/recurrent cervical cancer. The prognosis remains poor and effective second line options are urgently needed. Methods We searched the English-language medical literature as well as relevant guideline databases, published from January 1981 to December 2015 and identified publications related to cervical cancer and its therapies. Our effort was to highlight the available treatment options in the setting of recurrent/metastatic disease. Results Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease after platinum failure is still problematic. Overall, there is a trend in terms of longer overall survival (OS) and better quality of life for the combination of cisplatin/paclitaxel (PC) as compared to the doublets of cisplatin/topotecan (TC), cisplatin/vinorelbine (VC), and cisplatin/gemcitabine (GC). Currently available single agents beyond first-line platinum-based therapy have limited efficacy in this setting and include topoisomerase inhibitors, vinca alkaloids, taxanes, alkylating agents and antimetabolites. Several targeted therapies have demonstrated activity in advanced cervical cancer. Bevacizumab has been evaluated in a phase III trial using doublets of cisplatin with paclitaxel or topotecan and has been approved in the first-line setting by the U. S. Food and Drug Administration. Selective targeting of angiogenic kinases by tyrosine kinase inhibitors (TKIs) may represent a novel therapeutic tool in this setting, but its use alone or in combination with CT is still investigational. Early reports have implicated PI3KCA somatic mutations suggesting that mTOR-targeted agents should be explored in this disease. Development of the immune checkpoint programmed cell death 1 (PD-1) and T-lymphocyte–associated molecule-4 (CTLA-4) inhibitors have been of considerable interest, leading to ongoing phase II studies in patients with advanced cervical cancer. Conclusions Progress in the management of recurrent and advanced cervical cancer patients has been slow and restricted to palliative intent. These patients should be considered for clinical trials of novel targeted agents and/or immunotherapy. © 2016 Elsevier Ireland Ltd 108 164 174

Published
2016

14. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

Author

Osman Ilhan, Rıdvan Ali, Zafer Baslar, Ibrahim C. Haznedaroglu, Orhan Ayyildiz, Diyar Z. Akkaynak, Ugur Ozbek, Leylagül Kaynar, Mehmet Sönmez, Demet Aydin, Akif Selim Yavuz, Bülent Ündar, Ilkiz M. Dag, Mustafa Pehlivan, Güray Saydam, Birol Guvenc, Olga Meltem Akay, Simten Dagdas, Çukurova Üniversitesi, Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı., Ali, Rıdvan, and Ege Üniversitesi

Subjects
Male, Pyrimidine derivative, Peripheral occlusive artery disease, Antagonists and inhibitors, Treatment response, Tyrosine-kinase inhibitor, 0302 clinical medicine, tyrosine kinase inhibitor, Antineoplastic agents, Clinical endpoint, Medicine, Pharmacology (medical), Treatment outcome, Drug safety, Philadelphia Chromosome Positive, Fusion proteins, bcr-abl, General Medicine, Amn107, Multicenter study, Chronic Myeloid Leukemia, Imatinib, Protein Tyrosine Kinase Inhibitor, Clinical trial, Cholesterol, Antineoplastic agent, 030220 oncology & carcinogenesis, Interferon, Cancer chemotherapy, Treatment indication, Human, medicine.medical_specialty, Early molecular response, Protein kinase inhibitors, Phosphate, Cancer mortality, Major clinical study, Side effect, Triacylglycerol, Article, Treatment duration, 03 medical and health sciences, Alkaline phosphatase, Humans, Adverse effect, nilotinib, Aged, Pharmacology, Pharmacology & pharmacy, Upper respiratory tract infection, Follow up, Leukopenia, BCR-ABL1, Influenza, ComputingMethodologies_PATTERNRECOGNITION, Triacylglycerol lipase, Hyperglycemia, Immunology, 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Alkaline phosphatase blood level, Heart infarction, Survival, Blast cell crisis, Amylase blood level, Imatinib-resistant, Phosphate blood level, Turkey (republic), BCR ABL protein, hemic and lymphatic diseases, Middle aged, Cerebrovascular disease, Drug withdrawal, Follow-up, breakpoint cluster region, Myeloid leukemia, Anemia, molecular response, Triacylglycerol blood level, ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, Cholesterol blood level, Protein kinase inhibitor, Hypertension, Female, Alanine aminotransferase blood level, Leukemia, myelogenous, chronic, BCR-ABL positive, InformationSystems_MISCELLANEOUS, Chronic myelogenous leukemia, medicine.drug, Cessation, Adult, Neutropenia, medicine.drug_class, Ischemic heart disease, Newly diagnosed, Rating scale, chronic myeloid leukemia, Internal medicine, Rash, Alpha plus cytarabine, Prospective study, Phase 2 clinical trial, Bilirubin blood level, business.industry, Pruritus, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, Amylase, Bilirubin, Hair loss, Philadelphia 1 chromosome, Thrombocytopenia, Triacylglycerol lipase blood level, Drug efficacy, Outcome assessment, Pyrimidines, Young adult, Nilotinib, Alanine aminotransferase, business, Prospective studies, Constipation, 030215 immunology
Abstract

PubMed ID: 27501474, Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL1 ? 0.1% on the International Scale [BCR-ABL1IS]) by 12 months. Methods: Patients with newly diagnosed CML-CP were treated with nilotinib 300 mg twice daily. This analysis was based on the first 12 months of follow-up in a 24-month study. Results and Conclusions: Of 112 patients enrolled, 66.1% (80% CI, 59.7–72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1IS ? 0.0032%) by 12 months. During the first year of treatment, 1 patient progressed to blast crisis and 2 patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides. These results support the use of nilotinib 300 mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP. © 2016 Informa UK Limited, trading as Taylor & Francis Group., Novartis Pharmaceuticals Corporation, This study was funded by Novartis Pharmaceuticals Corporation.

Published
2016

15. RET kinase alterations in targeted cancer therapy.

Author

Liu X, Hu X, Shen T, Li Q, Mooers BHM, and Wu J

Abstract

The rearranged during transfection (RET) gene encodes a protein tyrosine kinase. RET alterations by point mutations and gene fusions were found in diverse cancers. RET fusions allow abnormal expression and activation of the oncogenic kinase, whereas only a few of RET point mutations found in human cancers are known oncogenic drivers. Earlier studies of RET-targeted therapy utilized multi-targeted protein tyrosine kinase inhibitors (TKIs) with RET inhibitor activity. These multi-targeted TKIs often led to high-grade adverse events and were subject to resistance caused by the gatekeeper mutations. Recently, two potent and selective RET TKIs, pralsetinib (BLU-667) and selpercatinib (LOXO-292), were developed. High response rates to these selective RET inhibitors across multiple forms of RET alterations in different types of cancers were observed in clinical trials, demonstrating the RET dependence in human cancers harboring these RET lesions. Pralsetinib and selpercatinib were effective in inhibiting RET V804L/M gatekeeper mutants. However, adaptive mutations that cause resistance to pralsetinib or selpercatinib at the solvent front RET G810 residue have been found, pointing to the need for the development of the next-generation of RET TKIs., Competing Interests: All authors declared that there are no conflicts of interest., (© The Author(s) 2020.)

Published
2020
Full Text
View/download PDF

16. Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study

Author

Dal, Mehmet Sinan, Korkmaz, Serdal, Berber, Ilhami, Sahin, Deniz Goren, Dogu, Mehmet Hilmi, Ayyildiz, Orhan, Nizam, Ilknur, Albayrak, Murat, Esen, Ramazan, Namdaroglu, Sinem, ŞENCAN, MEHMET, AKAY, OLGA MELTEM, Hacioglu, Sibel, Yildirim, Rahsan, Eser, Ali, TOMBAK, ANIL, Pala, Cigdem, İLHAN, OSMAN, [Korkmaz, Serdal] Kayseri Educ & Res Hosp, Div Hematol, TR-38100 Kayseri, Turkey -- [Pala, Cigdem] Erciyes Univ, Dept Hematol, Kayseri, Turkey -- [Dal, Mehmet Sinan -- Ayyildiz, Orhan] Dicle Univ, Dept Hematol, Diyarbakir, Turkey -- [Berber, Ilhami -- Nizam, Ilknur] Inonu Univ, Dept Hematol, Malatya, Turkey -- [Sahin, Deniz Goren -- Akay, Olga Meltem] Osmangazi Univ, Dept Hematol, Eskisehir, Turkey -- [Dogu, Mehmet Hilmi -- Hacioglu, Sibel] Pamukkale Univ, Dept Hematol, Denizli, Turkey -- [Albayrak, Murat] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Hematol, Ankara, Turkey -- [Namdaroglu, Sinem] Ankara Oncol Educ & Res Hosp, Dept Hematol, Ankara, Turkey -- [Ilhan, Osman] Ankara Univ, Dept Hematol, Ibni Sina Hosp, TR-06100 Ankara, Turkey -- [Esen, Ramazan] Yuzuncu Yil Univ, Dept Hematol, Van, Turkey -- [Sencan, Mehmet] Cumhuriyet Univ, Dept Hematol, Sivas, Turkey -- [Yildirim, Rahsan] Ataturk Univ, Dept Hematol, Erzurum, Turkey -- [Eser, Ali] Marmara Univ, Dept Hematol, Istanbul, Turkey -- [Tombak, Anil] Mersin Univ, Dept Hematol, Mersin, Turkey, and albayrak, murat -- 0000-0003-4025-741X

Subjects
blood toxicity, Male, age distribution, protein tyrosine kinase inhibitor, retrospective study, very elderly, pyrimidine derivative, Dasatinib, diarrhea, gastrointestinal symptom, thrombocytopenia, rash, hydroxyurea, Turkey (republic), hemic and lymphatic diseases, musculoskeletal pain, antineoplastic agent, Aged, 80 and over, progression free survival, protein kinase inhibitor, Chronic myeloid leukemia, chromosome analysis, clinical trial, Protein-Tyrosine Kinases, anemia, aged, female, Treatment Outcome, priority journal, drug withdrawal, multicenter study (topic), Imatinib Mesylate, survival rate, overall survival, Antineoplastic Agents, patient compliance, Article, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, neutropenia, Humans, controlled study, drug fatality, human, survival time, Protein Kinase Inhibitors, nilotinib, antagonists and inhibitors, Retrospective Studies, treatment response, protein tyrosine kinase, sex ratio, major clinical study, mortality, clinical feature, Elderly patients, multicenter study, Pyrimidines, imatinib, 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Aged, Antineoplastic Agents/*administration & dosage, Dasatinib/therapeutic use, Female, Imatinib Mesylate/*administration & dosage/adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/mortality, Patient Compliance, Protein Kinase Inhibitors/*administration & dosage/adverse effects, Protein-Tyrosine Kinases/antagonists & inhibitors, Pyrimidines/therapeutic use, edema
Abstract

WOS: 000355733300008, PubMed ID: 25257190, AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy. MethodsData including the clinical characteristics, therapeutic outcomes and compliance with TKI therapy of elderly patients with chronic myeloid leukemia aged >65years were collected from 13 institutions in Turkey, retrospectively. ResultsA total of 69 patients (27 [39%] men, 42 [61%] women) were evaluated retrospectively. The median age of the patients was 71years (range 66-85years). Of the patients, 66 (96%) were in the chronic phase and three (4.3%) were in the accelerated phase when diagnosed. A total of 63 (91.3%) patients were receiving imatinib as the first-line therapy. The initial dose of imatinib was 400mg/day in 59 patients (93.6%). Imatinib treatment induced 57 (90.5%) complete hematological responses at 3months, 29 (46%) complete cytogenetic responses at 6months and 49 (77.7%) major molecular responses at 12months. As a result, nilotinib and dasatinib were used in 14 patients as second-line therapy. Second-line TKI induced nine complete hematological responses (64.3%) at 3months, four complete cytogenetic responses (28.6%) at 12months and seven major molecular responses (50%) at 18months. A total of 56 of the patients (81.2%) are still alive. The median overall survival and progression-free survival rates were 35months (range 1-95months) and 17months (range 0.8-95months), respectively. ConclusionElderly patients should receive TKI according to the same guidelines that apply to younger patients. Geriatr Gerontol Int 2015; 15: 729-735.

Published
2015

17. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.

Author

Haeusler G.M., Bajel A., van Hal S.J., Chen S.C., Milliken S.T., Morrissey C.O., Tam C.S., Szer J., Weinkove R., Slavin M.A., Heath C.H., Grigg A., Clark J., Fleming S., Yannakou C.K., Haeusler G.M., Bajel A., van Hal S.J., Chen S.C., Milliken S.T., Morrissey C.O., Tam C.S., Szer J., Weinkove R., Slavin M.A., Heath C.H., Grigg A., Clark J., Fleming S., and Yannakou C.K.

Abstract

There is a strong argument for the use of antifungal prophylaxis in high-risk patients given the significant mortality associated with invasive fungal disease, the late identification of these infections, and the availability of safe and well-tolerated prophylactic medications. Clinical decisions about which patients should receive prophylaxis and choice of antifungal agent should be guided by risk stratification, knowledge of local fungal epidemiology, the efficacy and tolerability profile of available agents, and estimates such as number needed to treat and number needed to harm. There have been substantial changes in practice since the 2008 guidelines were published. These include the availability of new medications and/or formulations, and a focus on refining and simplifying patient risk stratification. Used in context, these guidelines aim to assist clinicians in providing optimal preventive care to this vulnerable patient demographic.Copyright © 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Published
2015

18. Metastatic thyroid cancer: Three extraordinary cases highlighting management principles and recent advances.

Author

Murali K. and Murali K.

Abstract

Aims: Thyroid cancer represents less than 1% of all human cancers. Metastatic thyroid cancer forms an even rarer entity. There have been a number of recent advances in treatment, namely in molecular profiling and targeted therapy. Method(s): We reviewed the latest literature as well as all cases of metastatic thyroid cancer managed at our institution over the past five years. We selected three cases that best highlight key management principles. Result(s): The first case is of a 27 year old Vietnamese male with metastatic follicular cancer on a background of thyroid lobectomy 7 years prior for follicular adenoma. He presented with symptomatic pulmonary and vertebral metastases. Retrospective review of the original lobectomy revealed a missed minimally invasive follicular carcinoma. He was commenced on systemic therapy with the tyrosine kinase inhibitor sorafenib, then changed to lenvatinib on progression. He was briefly transitioned to MEK inhibitor trametinib to facilitate tumour re-differentiation and sensitisation to radioactive iodine. The second case is of a BRAF mutation positive metastatic papillary thyroid cancer in a 57 year old East Timorese female. Her condition was complicated by DIC and SVC obstruction. Commencement of BRAF inhibitor vemurafenib resulted in clinical and haematological improvement allowing for discharge home. The third case is of a 28 year old Caucasian male with a new diagnosis of sporadic MEN2A syndrome. Diagnosis was made during an inpatient admission for back pain. Investigations revealed metastatic medullary thyroid cancer complicated by extensive bone metastases. Screening detected phaeochromocytoma and primary hyperparathyroidism. Radiotherapy for bone metastases was commenced and access for vandetanib was arranged, after considering cabozantinib through clinical trial. Unfortunately, he developed tumour-induced DIC and significant functional decline. He was discharged home with palliative care. Conclusion(s): All three cases high

Published
2015

20. Synthesis, characterization, electrochemical behavior and in vitro protein tyrosine kinase inhibitory activity of the cymene-halogenobenzohydroxamato [Ru(eta(6)-cymene)(bha)Cl] complexes

Author

Maxim L. Kuznetsov, Armando J. L. Pombeiro, Xianmei Shang, Telma F. S. Silva, Luísa M. D. R. S. Martins, M. Fátima C. Guedes da Silva, and Qingshan Li

Subjects
Platinum complexes, Stereochemistry, Redox potentials, chemistry.chemical_element, Ruthenium(II) complexes, Molecular-structure, Biochemistry, Redox, Coordination complex, Inorganic Chemistry, X-ray, Design strategies, Synthesis, Ferrocene derivatives, Materials Chemistry, Electrochemistry, Ruthenium(II) arene complexes, Molecular orbital, Physical and Theoretical Chemistry, Protein tyrosine kinase inhibitor, chemistry.chemical_classification, Crystal-structures, Chemistry, Ligand, Organic Chemistry, Carbon-13 NMR, Ruthenium, Coordination chemistry, Anticancer agents, Proton NMR, Cyclic voltammetry
Abstract

The ruthenium(II)–cymene complexes [Ru(η 6 -cymene)(bha)Cl] with substituted halogenobenzohydroxamato (bha) ligands (substituents = 4-F, 4-Cl, 4-Br, 2,4-F 2 , 3,4-F 2 , 2,5-F 2 , 2,6-F 2 ) have been synthesized and characterized by elemental analysis, IR, 1 H NMR, 13 C NMR, cyclic voltammetry and controlled-potential electrolysis, and density functional theory (DFT) studies. The compositions of their frontier molecular orbitals (MOs) were established by DFT calculations, and the oxidation and reduction potentials are shown to follow the orders of the estimated vertical ionization potential and electron affinity, respectively. The electrochemical E L Lever parameter is estimated for the first time for the various bha ligands, which can thus be ordered according to their electron-donor character. All complexes exhibit very strong protein tyrosine kinase (PTK) inhibitory activity, even much higher than that of genistein, the clinically used PTK inhibitory drug. The complex containing the 2,4-difluorobenzohydroxamato ligand is the most active one, and the dependences of the PTK activity of the complexes and of their redox potentials on the ring substituents are discussed.

Published
2013

21. Renal carcinoma with inferior vena cava tumour thrombus: An Australian experience.

Author

Frydenberg M., Winter M., Spernat D., Appu S., Tay Y.K., Frydenberg M., Winter M., Spernat D., Appu S., and Tay Y.K.

Abstract

Introduction: Renal cell carcinoma is known to extend into the IVC in 4-10% of cases.1-3 Despite the technical difficulty, cytoreductive nephrectomy has a role in palliation and may increase survival. We present a retrospective, multi-institution case series of patients undergoing radical nephrectomy and IVC thrombectomy. Material(s) and Method(s): We conducted a retrospective review of the medical records of patients undergoing a radical nephrectomy with caval thrombectomy performed by three uro-oncology units from June 1997 to June 2011. Patient demographics, thrombus extension, tumour size, length of stay, blood loss and complications were recorded. Outcome measures were based on disease progression and patient status at time of follow-up. Result(s): 29 patients were identified with 18 males and 11 females. The male mean age was 54, the female mean age was 63, and the overall mean age was 58 years. The patients were classified according to Neves score. 14 patients had Neves classification of I, 8 Neves II, 2 Neves III, and 5 Neves IV. Mean tumour size was 103.9mm (range 25-180). Mean blood loss was 1580mL (range 90-8500). Mean operative time (n=22) was 180 minutes (range 70-390). Mean LOS (n=18) was 8.8 days (range 5-22). 31% of patients had a positive surgical margin. Complication and follow-up data was limited. Complication data was available for 9 patients. There was one grade V complication, one IVb, one IIIa, six II, and one grade I complication. Followup data was available for 15 patients. Of these the mean survival time post operatively was 17.7 months (range 3-90) Conclusion(s): Despite the invasive nature of radical nephrectomy with caval thrombectomy, blood loss, LOS and complication rates are acceptable. Mean survival post surgery of 17.7 months will likely increase in the Tyrosine Kinase Inhibitor era. However, one must consider the physiological status of the patient prior to embarking on surgical intervention.

Published
2012

22. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC

Author

Gately, Kathy, O'Flaherty, John, Cappuzzo, Frederico, Pirker, Robert, Kerr, Keith, O'Byrne, Kenneth, Gately, Kathy, O'Flaherty, John, Cappuzzo, Frederico, Pirker, Robert, Kerr, Keith, and O'Byrne, Kenneth

Abstract

Free to read The majority of patients with non-small-cell lung cancer (NSCLC) present with advanced disease, with targeted therapies providing some improvement in clinical outcomes. The epidermal growth factor receptor (EGFR) tyrosine kinase (TK) plays an important role in the pathogenesis of NSCLC. Tyrosine kinase inhibitors (TKIs), which target the EGFR TK domain, have proven to be an effective treatment strategy; however, patient responses to treatment vary considerably. Therefore, the identification of patients most likely to respond to treatment is essential to optimise the benefit of TKIs. Tumour-associated activating mutations in EGFR can identify patients with NSCLC who are likely to have a good response to TKIs. Nonetheless, the majority of patients relapse within a year of starting treatment. Studies of tumours at relapse have demonstrated expression of a T790M mutation in exon 20 of the EGFR TK domain in approximately 50% of cases. Although conferring resistance to reversible TKIs, these patients may remain sensitive to new-generation irreversible/panerb inhibitors. A number of techniques have been employed for genotypic assessment of tumourassociated DNA to identify EGFR mutations, each of which has advantages and disadvantages. This review presents an overview of the current methodologies used to identify such molecular markers. Recent developments in technology may make the monitoring of changes in patients' tumour genotypes easier in clinical practice, which may enable patients' treatment regimens to be tailored during the course of their disease, potentially leading to improved patient outcomes.

Published
2012

23. Receptor tyrosine kinases and their activation in melanoma

Author

Easty, David, Gray, Steven, O'Byrne, Kenneth, O'Donnell, Dearbhaile, Bennett, Dorothy, Easty, David, Gray, Steven, O'Byrne, Kenneth, O'Donnell, Dearbhaile, and Bennett, Dorothy

Abstract

Free to read Receptor tyrosine kinases (RTKs) and their downstream signalling pathways have long been hypothesized to play key roles in melanoma development. A decade ago, evidence was derived largely from animal models, RTK expression studies and detection of activated RAS isoforms in a small fraction of melanomas. Predictions that overexpression of specific RTKs implied increased kinase activity and that some RTKs would show activating mutations in melanoma were largely untested. However, technological advances including rapid gene sequencing, siRNA methods and phospho-RTK arrays now give a more complete picture. Mutated forms of RTK genes including KIT, ERBB4, the EPH and FGFR families and others are known in melanoma. Additional over- or underexpressed RTKs and also protein tyrosine phosphatases (PTPs) have been reported, and activities measured. Complex interactions between RTKs and PTPs are implicated in the abnormal signalling driving aberrant growth and survival in malignant melanocytes, and indeed in normal melanocytic signalling including the response to ultraviolet radiation. Kinases are considered druggable targets, so characterization of global RTK activity in melanoma should assist the rational development of tyrosine kinase inhibitors for clinical use. © 2011 John Wiley & Sons A/S.

Published
2011

24. Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo

Author

Weel, V. van, Deckers, M.M.L., Grimbergen, J.M., Leuven, K.J.M. van, Lardenoye, J.W.H.P., Schlingemann, R.O., Nieuw Amerongen, G.P. van, Bockel, J.H. van, Hinsbergh, V.W.M. van, and Quax, P.H.A.

Subjects
Male, Vascular Endothelial Growth Factor A, Biomedical Research, protein tyrosine kinase inhibitor, beta galactosidase, Gene Expression, animal cell, Mice, Ischemia, angiography, pain, Amputation, Myoglobin, messenger RNA, adenovirus vector, Gene Therapy, RNA analysis, Middle Aged, semaxanib, Female, animal experiment, Genetic Vectors, Neovascularization, Physiologic, Muscle Fibers, Adenoviridae, in vivo study, angina pectoris, vascularization, Animals, Humans, controlled study, muscle ischemia, gastrocnemius muscle, RNA, Messenger, drug inhibition, skeletal muscle, Muscle, Skeletal, Biology, protein expression, mouse, Aged, nonhuman, vasculotropin, muscle function, animal model, capillary density, Capillaries, vasculotropin A, Peripheral vascular disease, myotube, Angiogenesis, Vascular endothelial growth factor
Abstract

Therapeutic angiogenesis using vascular endothelial growth factor (VEGF) is considered a promising new therapy for patients with arterial obstructive disease. Clinical improvements observed consist of improved muscle function and regression of rest pain or angina. However, direct evidence for improved vascularization, as evaluated by angiography, is weak. In this study, we report an angiogenesis-independent effect of VEGF on ischemic skeletal muscle, ie, upregulation of myoglobin after VEGF treatment. Mice received intramuscular injection with adenoviral VEGF-A or either adenoviral LacZ or PBS as control, followed by surgical induction of acute hindlimb ischemia at day 3. At day 6, capillary density was increased in calf muscle of Ad. VEGF-treated versus control mice (P

Published
2004

25. Nitric oxide production by macrophages stimulated by antigen-binding T-cell factors

Author

Redegeld, F.A., Heijdra, B., Knippels, M.-C., Garssen, J., Nijkamp, F.P., Sub Immunopharmacology, Sub Biology Education begr. 01-01-2013, Sub General Pharmacology, and Biology Education

Subjects
Lipopolysaccharides, Picryl chloride factor, Indoles, protein tyrosine kinase inhibitor, T-Lymphocytes, animal cell, Picryl Chloride, Picryl chloride, Maleimides, chemistry.chemical_compound, Mice, 1 fluoro 2,4 dinitrobenzene, T lymphocyte, Immunology and Allergy, antigen binding, Enzyme Inhibitors, conference paper, Protein Kinase C, Lymphokines, biology, Kinase, nitric oxide synthase, lipopolysaccharide, Protein-Tyrosine Kinases, Genistein, 1 fluoro 2, Cell biology, Nitric oxide synthase, Biochemistry, priority journal, Signal transduction, Tyrosine kinase, signal transduction, culture medium, Immunology, binding protein, protein kinase C inhibitor, contact sensitivity, Nitric Oxide, Nitric oxide, Cell Line, Animals, controlled study, Antigens, 4 dinitrobenzene, nitrite, Protein kinase C, mouse, nonhuman, Antigen-specific T-cell factor, Binding protein, Macrophages, molecular weight, Macrophage Activation, Isoflavones, chemistry, biology.protein, Dinitrofluorobenzene
Abstract

Contact sensitivity to small molecular weight compounds is accompanied by the production of antigen-specific T-cell factors (TCF) shortly after skin application of the sensitizing agents. In this study, we show that macrophages can be activated by these TCF to generate large amounts of nitric oxide (NO). Incubation of the murine macrophage cell line J774 for 24 h with TCF raised against dinitrofluorobenzene (DNFB) or picryl chloride (PCL) resulted in a nitrite accumulation in the culture medium. Priming of J774 with rIFN-gamma synergistically enhanced stimulation of NO synthesis by DNFB-F and PCL-F. A possible contribution of lipopolysaccharide (LPS) as a contaminant of the TCF was excluded. The enhanced production of NO after stimulation with TCF was accompanied with an increased expression of inducible NO synthase. Inclusion of inhibitors of protein tyrosine kinase and protein kinase C inhibited the TCF-induced NO production by macrophages, indicating the involvement of both protein kinases in the signaling pathway activated by TCF. Since NO is an important biological mediator with many immunoregulatory properties, our results suggest a potential role for increased NO production by macrophages in the elicitation of contact sensitivity to small molecular weight compounds.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results